Clinical Trials Browser

Burkitt Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Peripheral, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Extranodal NK-T-Cell

NCT00286793 2011-06-29

Safety and Efficacy Study of AT-101 in Combination With Docetaxel and Prednisone in Men With HRPC

Phase 1/2 Completed

76 enrolled

Genitourinary

Neoplasms, Prostatic Neoplasms

NCT00571675 2010-11-09

A Study Comparing AT-101 in Combination With Docetaxel and Prednisone Versus Docetaxel and Prednisone in Men With Chemotherapy-Naïve Metastatic Hormone Refractory Prostate Cancer (HRPC)

Phase 2 Completed

220 enrolled

Genitourinary

Disease, Neoplasm Metastasis, Prostatic Neoplasms

NCT00440388 2010-08-27

Safety & Efficacy Study of AT-101 in Combination w/ Rituximab in Previously Untreated Grade I-II Follicular Non-Hodgkin's Lymphoma

Phase 2 Completed

23 enrolled

Lymphoid

Lymphoma, Lymphoma, Follicular, Neoplasms

NCT00544960 2010-08-27

A Randomized Phase 2 Study of AT-101 in Combination With Docetaxel in Relapsed/Refractory Non-Small Cell Lung Cancer

Phase 2 Completed

106 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT00286806 2010-08-24

A Study of Single-Agent AT-101 in Men With Hormone Refractory Prostate Cancer

Phase 1/2 Completed

27 enrolled

Genitourinary

Hormone Refractory Prostate Cancer

NCT00397293 2010-08-24

Study of AT-101 in Combination With Topotecan in Relapsed/Refractory Small Cell Lung Cancer

Phase 1/2 Completed

36 enrolled

Thoracic

Neoplasms, Small Cell Lung Carcinoma

NCT00286780 2010-08-13

Phase 2 Safety and Efficacy Study of AT-101 in Combination With Rituximab in Patients With Chronic Lymphocytic Leukemia

Phase 2 Completed

19 enrolled

LymphoidOther hematologic neoplasm

Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell

Clinical Trials

Gossypol in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme

R-(-)-Gossypol and Androgen Ablation Therapy in Treating Patients With Newly Diagnosed Metastatic Prostate Cancer

Gossypol Acetic Acid in Treating Patients With Recurrent, Metastatic, or Primary Adrenocortical Cancer That Cannot Be Removed By Surgery

R-(-)-Gossypol Acetic Acid, Cisplatin, and Etoposide in Treating Patients With Advanced Solid Tumors or Extensive Stage Small Cell Lung Cancer

Gossypol, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

Safety and Efficacy Study of AT-101 in Combination With Docetaxel and Prednisone in Men With HRPC

A Study Comparing AT-101 in Combination With Docetaxel and Prednisone Versus Docetaxel and Prednisone in Men With Chemotherapy-Naïve Metastatic Hormone Refractory Prostate Cancer (HRPC)

Safety & Efficacy Study of AT-101 in Combination w/ Rituximab in Previously Untreated Grade I-II Follicular Non-Hodgkin's Lymphoma

A Randomized Phase 2 Study of AT-101 in Combination With Docetaxel in Relapsed/Refractory Non-Small Cell Lung Cancer

A Study of Single-Agent AT-101 in Men With Hormone Refractory Prostate Cancer

Study of AT-101 in Combination With Topotecan in Relapsed/Refractory Small Cell Lung Cancer

Phase 2 Safety and Efficacy Study of AT-101 in Combination With Rituximab in Patients With Chronic Lymphocytic Leukemia